Literature DB >> 7628194

Increased recovery of group B Streptococcus by the inclusion of rectal culturing and enrichment.

M W Platt1, J C McLaughlin, G J Gilson, M F Wellhoner, L J Nims.   

Abstract

Detection of intrapartum carriage of group B streptococcus (GBS) and subsequent antibiotic prophylaxis may prevent GBS infections in neonates. Because the gastrointestinal tract is the primary source of this organism, detection of carrier status requires both rectal and vaginal swabs. Vaginal swabs from 651 obstetric outpatients were plated onto 5% sheep blood agar. A second vaginal and a rectal swab were collected and incubated overnight in an enrichment medium of Todd-Hewitt broth containing antibiotics. By at least one method, 110 (16.9%) patients were positive for GBS. Only 31.8% of these positive patients were detected by direct culture of vaginal swabs. The use of vaginal swabs directly plated onto blood agar identified only three carriers not detected by another method. Inoculation of an enrichment broth with the vaginal swab and subsequent subculture detected 70.9% of the total. The use of both vaginal and rectal swabs with enrichment detected 97.3% of total GBS carriers. A subset of enrichment broths inoculated with vaginal and rectal specimens from 279 patients was tested for GBS by direct latex agglutination (Streptex; Murex Diagnostics, Inc., Norcross, GA, USA). Of the 90 broths that grew GBS on subculture, only 59 (65.6%) were positive by the direct agglutination method. The use of this method, although reducing processing time by 1 day, gave false-negative results for one-third of the GBS-positive broths. An accurate detection of the GBS carrier state can only be achieved by a combination of vaginal and rectal swabs incubated in enrichment broth and subcultured on blood agar.

Entities:  

Mesh:

Year:  1995        PMID: 7628194     DOI: 10.1016/0732-8893(95)00022-3

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  7 in total

1.  Evaluation of methods to increase the sensitivity and timeliness of detection of Streptococcus agalactiae in pregnant women.

Authors:  Sue B Overman; Douglas D Eley; Barry E Jacobs; Julie A Ribes
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

2.  A case of postpartum Group B streptococcal meningitis.

Authors:  Kylie Gayford; Ana McCarthy; William M Hague
Journal:  Obstet Med       Date:  2011-11-22

3.  Comparison of different sampling techniques and of different culture methods for detection of group B streptococcus carriage in pregnant women.

Authors:  Nabil A El Aila; Inge Tency; Geert Claeys; Bart Saerens; Piet Cools; Hans Verstraelen; Marleen Temmerman; Rita Verhelst; Mario Vaneechoutte
Journal:  BMC Infect Dis       Date:  2010-09-29       Impact factor: 3.090

4.  Culture-based method with performance comparable to that of PCR-based methods for detection of group B Streptococcus in screening samples from pregnant women.

Authors:  Benjamin R Berg; Jeana L Houseman; Michelle A Garrasi; Carol L Young; Duane W Newton
Journal:  J Clin Microbiol       Date:  2013-01-23       Impact factor: 5.948

5.  Evaluation of Trans-Vag broth, colistin-nalidixic agar, and CHROMagar StrepB for detection of group B Streptococcus in vaginal and rectal swabs from pregnant women in South Africa.

Authors:  Gaurav Kwatra; Shabir A Madhi; Clare L Cutland; Eckhart J Buchmann; Peter V Adrian
Journal:  J Clin Microbiol       Date:  2013-05-22       Impact factor: 5.948

Review 6.  Epidemiology of group B streptococcal disease in the United States: shifting paradigms.

Authors:  A Schuchat
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

7.  Diagnostic Performance of Various Methodologies for Group B Streptococcus Screening in Pregnant Woman in China.

Authors:  Kankan Gao; Qiulian Deng; Lianfen Huang; Chien-Yi Chang; Huamin Zhong; Yongqiang Xie; Xiaoshan Guan; Haiying Liu
Journal:  Front Cell Infect Microbiol       Date:  2021-05-24       Impact factor: 5.293

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.